MASHINIi

C4 Therapeutics, Inc..

CCCC.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

C4 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapeutics to treat cancer and other diseases. The company's technology platform utilizes small molecule drugs to selectively degrade disease-causing proteins by harnessing the b...Show More

Ethical Profile

Mixed.

C4 Therapeutics develops targeted protein degraders for cancer, a core mission supporting "Better Health for All." Employees report competitive compensation (Glassdoor 4.2/5 stars) and benefits. However, critics note CEO compensation, US$3.8 million in 2023, as above average for similar biotech firms; broader pay equity data is undisclosed. The company maintains a formal whistleblower protection policy and confidential hotline, with initial reports allegedly investigated within 30 days. However, public data on regulatory fines, transparency, anti-corruption, environmental impact, animal welfare (despite likely animal testing), or cybersecurity measures is unavailable.

Value Scores

Better Health for All10
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect30
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business-40
-100100
Kind to Animals-40
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

10

C4 Therapeutics' entire business is dedicated to discovering and developing targeted protein degradation therapeutics to treat cancer and other diseases, aiming to deliver transformative health benefits. The company has no revenue from products with negative health outcomes, as its focus is on developing novel therapies. For the full year ended December 31, 2024, the company invested $110.6 million in Research and Development, focusing on new medicines for cancer, inflammation, and neuro-degenerative diseases.

1
The company offers extensive support for its healthcare workforce, including unlimited paid time off, two annual company-wide shutdowns, a sabbatical program, and a generous 401(k) match.
2
C4 Therapeutics also demonstrates strong healthcare data responsibility with annual cybersecurity training, 24/7 Security Operations Center monitoring, multi-factor authentication, and geographically distributed data backups.
3
Clinical trials are designed to respect human rights, including vulnerable populations, and the company is committed to publishing all clinical research results.
4
However, the company's risk transparency is limited, as it refers to SEC filings for detailed risk factors rather than providing comprehensive public data directly.
5
The company's preventative health measures and mental health initiatives are primarily focused on employee well-being, such as access to the Calm App and an Employee Assistance Program, rather than broader public health prevention.
6
Similarly, healthcare education efforts are limited to a partnership supporting STEM education in local public schools.
7
The company's investigational therapies are for patients who have received multiple prior treatments, indicating a focus on later-line patients rather than broader vulnerable populations.
8

Fair Money & Economic Opportunity

0

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics.

1
Its core business does not involve offering lending, deposit, or other financial services to consumers. Consequently, all KPIs related to financial products, pricing, fees, and customer financial outcomes are not applicable. The company intends to retain all future earnings to finance its business growth and development, which is a standard profit retention policy, not a community finance reinvestment.
2
While the company provides employees with opportunities for equity ownership, this pertains to employee benefits, not customer wealth-building outcomes from financial products.
3
Information about clinical trials must be submitted to the NIH for public dissemination, but this relates to medical data, not customer financial data portability.
4
The company also states a commitment to diversity, equity, and inclusion in the workplace, which refers to internal employee practices, not financial inclusion programs for external underserved segments.
5
There is no evidence of consumer credit products, associated APRs, exploitative fees, or any regulatory findings related to lending practices.

Fair Pay & Worker Respect

30

Multiple articles state that no regulatory actions, violations, fines, or compliance issues related to labor laws are mentioned for C4 Therapeutics.

1
The company offers competitive and generous health, dental, eye, HSA, and FSA plans.
2
Additionally, employees report benefits such as 401K matching, 11 paid holidays, summer hours, and unlimited PTO.
3
These benefits are reported to include family coverage and mental health services.
4

Fair Trade & Ethical Sourcing

0

No evidence available to assess C4 Therapeutics, Inc. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

-40

C4 Therapeutics has a formal whistleblower protection policy, which includes a confidential reporting hotline accessible via a secure web form and a toll-free number.

1
The policy emphasizes confidentiality, and financial and accounting reports are forwarded to the Audit Committee Chair.
2
However, there is no evidence provided regarding independent investigation processes for these reports.

Kind to Animals

-40

C4 Therapeutics conducts pre-clinical studies of its drugs on animals to assess product safety.

1
The company explicitly stated in a report that it "exploits animals for product testing."
2
There is no evidence of a policy to reduce or eliminate animal testing, nor any measurable goals or accountability for such practices.

No War, No Weapons

0

No evidence available to assess C4 Therapeutics, Inc. on No War, No Weapons.

Planet-Friendly Business

0

No quantitative sustainability or ESG data relevant to the Planet-Friendly Business value is available for C4 Therapeutics, Inc. across the provided articles.

1
The articles explicitly state that no such data, performance metrics, targets, or initiatives are included.
2

Respect for Cultures & Communities

0

No specific, concrete data points relevant to the 'Respect for Cultures & Communities' value for CCCC.US were found in the provided articles. The articles discuss general industry news or promotional content for industry organizations, without providing any actionable evidence for the company's performance against the defined KPIs.

Safe & Smart Tech

0

The company notes compliance with various regulatory requirements concerning internal controls, including IT systems.

1
It also engages a third-party vendor for advice on compliance.
2

Zero Waste & Sustainable Products

0

No specific, concrete data points were found in the provided article to assess CCCC.US against the Zero Waste & Sustainable Products ethical value.

1
The article explicitly states it is a placeholder and contains no relevant information for any of the KPIs.
2

Own C4 Therapeutics, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.